Emlidus 10 mg+5 mg (Tablet)

Unit Price: ৳ 30.00 (1 x 14: ৳ 420.00)
Strip Price: ৳ 420.00

Medicine Details

Category Details
Generic Empagliflozin linagliptin
Company Opsonin pharma ltd
Also available as
Emlidus 25 mg tablet

Indications

  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Pharmacology

  • Linagliptin inhibits DPP-4 enzyme
  • Linagliptin increases concentrations of active incretin hormones
  • Empagliflozin is an inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
  • Empagliflozin reduces renal reabsorption of filtered glucose
  • Empagliflozin increases urinary glucose excretion

Dosage & Administration

  • Recommended dose: 10 mg Empagliflozin and 5 mg Linagliptin once daily, taken in the morning, with or without food
  • Increased dose: Dose may be increased to 25 mg Empagliflozin and 5 mg Linagliptin once daily
  • Assess renal function before initiating this tablet
  • Do not initiate this tablet if eGFR is below 45 mL/min/1.73 m^2
  • Discontinue taking this tablet if eGFR falls below 45 ml/min/1.73 m^2

Interaction

  • Coadministration of Empagliflozin with diuretics
  • Coadministration of Empagliflozin with Insulin or Insulin secretagogues
  • Rifampin decreased Linagliptin exposure
  • SGLT2 inhibitors increase urinary glucose excretion
  • Measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors

Contraindications

  • Severe renal impairment, end-stage renal disease, or dialysis
  • History of hypersensitivity reaction to Linagliptin or Empagliflozin

Side Effects

  • Pancreatitis
  • Ketoacidosis
  • Volume Depletion
  • Urosepsis and Pyelonephritis
  • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
  • Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene)
  • Genital Mycotic Infections
  • Hypersensitivity Reactions
  • Severe and Disabling Arthralgia
  • Bullous Pemphigoid
  • Heart Failure

Pregnancy & Lactation

  • Not recommended during the second and third trimesters of pregnancy
  • Limited available data of this tablet in pregnant women

Precautions & Warnings

  • Precaution should be taken in some disease conditions like Pancreatitis, Hypotension, Ketoacidosis, Acute kidney injury
  • Hypoglycemia, Genital Mycotic Infections, Hypersensitivity etc.
  • Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with Linagliptin
  • Reports of ketoacidosis in patients with type 1 and type 2 diabetes mellitus
  • Empagliflozin can cause intravascular volume depletion
  • Treatment with SGLT2 inhibitors increases the risk for urinary tract infections

Overdose Effects

  • In the event of an overdose with this tablet, contact Poison Control Center
  • Employ the usual supportive measures as dictated by the patient’s clinical status

Therapeutic Class

  • Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Storage Conditions

  • Store below 30°C temperature
  • Keep away from light and wet place
  • Keep out of reach of children

Related Brands